PT948358E - Formulacoes de interferao liquidas e estaveis - Google Patents

Formulacoes de interferao liquidas e estaveis

Info

Publication number
PT948358E
PT948358E PT97952621T PT97952621T PT948358E PT 948358 E PT948358 E PT 948358E PT 97952621 T PT97952621 T PT 97952621T PT 97952621 T PT97952621 T PT 97952621T PT 948358 E PT948358 E PT 948358E
Authority
PT
Portugal
Prior art keywords
liquid
interferon
compositions
formulations
beta
Prior art date
Application number
PT97952621T
Other languages
English (en)
Inventor
Mary D Dibiasi
Mark Staples
Wen-Li Chung
Eric Scharin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT948358(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of PT948358E publication Critical patent/PT948358E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT97952621T 1996-12-24 1997-12-23 Formulacoes de interferao liquidas e estaveis PT948358E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3435396P 1996-12-24 1996-12-24

Publications (1)

Publication Number Publication Date
PT948358E true PT948358E (pt) 2004-10-29

Family

ID=21875893

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97952621T PT948358E (pt) 1996-12-24 1997-12-23 Formulacoes de interferao liquidas e estaveis

Country Status (28)

Country Link
EP (1) EP0948358B2 (pt)
JP (5) JP4878664B2 (pt)
KR (2) KR20000069664A (pt)
CN (2) CN1733296B (pt)
AT (1) ATE270899T1 (pt)
AU (1) AU738362B2 (pt)
BG (2) BG65171B1 (pt)
BR (1) BR9714434A (pt)
CA (1) CA2275890C (pt)
CZ (1) CZ300636B6 (pt)
DE (1) DE69729880T3 (pt)
DK (1) DK0948358T4 (pt)
EA (1) EA002754B1 (pt)
EE (2) EE04266B1 (pt)
ES (1) ES2224290T5 (pt)
HK (2) HK1025040A1 (pt)
HU (1) HU224222B1 (pt)
IL (1) IL130524A (pt)
IS (1) IS2070B (pt)
MX (1) MX337876B (pt)
NO (1) NO327844B1 (pt)
NZ (2) NZ336548A (pt)
PL (1) PL193447B1 (pt)
PT (1) PT948358E (pt)
SI (1) SI0948358T2 (pt)
SK (1) SK284989B6 (pt)
TR (1) TR199901968T2 (pt)
WO (1) WO1998028007A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04266B1 (et) * 1996-12-24 2004-04-15 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
EP1426058A3 (de) 1997-09-23 2004-07-28 Dr. Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
CN100448482C (zh) * 1999-05-31 2009-01-07 三菱化学株式会社 Hgf冻干制剂
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
WO2003061687A1 (en) * 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation High-concentration preparation of soluble thrombomodulin
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EP1628677B1 (en) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Protein stabilization in solution
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1682012A4 (en) * 2003-11-13 2008-09-24 Alza Corp COMPOSITION AND APPARATUS FOR TRANSDERMAL DELIVERY
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
KR101149454B1 (ko) * 2004-08-24 2012-05-25 간가와 겐지 생리활성 펩티드의 액상 제제
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005304486B2 (en) * 2004-11-10 2011-08-11 Novartis Vaccines And Diagnostics Inc. Deamidated interferon-beta
LT1845925T (lt) * 2005-01-12 2016-09-26 Biogen Ma Inc. Interferono-beta pateikimo būdas
WO2006079019A2 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
EP2264161A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA3123813A1 (en) * 2007-12-04 2009-06-11 Biogen Chesapeake Llc Improved glibenclamide formulations and methods for lyophilization thereof and lyophilates provided thereby
KR20100099298A (ko) 2007-12-20 2010-09-10 메르크 세로노 에스. 에이. Ｐｅｇ­인터페론­베타 제형
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2519475T5 (es) 2008-05-01 2018-07-02 Arecor Limited Formulación de una proteína
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
AU2011212440B2 (en) 2010-02-04 2015-01-22 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) * 2010-03-15 2011-09-15 Kurt Koch Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
KR20130132496A (ko) 2010-12-09 2013-12-04 마루이시세이야쿠가부시키가이샤 아세트아미노펜의 안정화제
MX359947B (es) * 2011-03-15 2018-10-17 Biogen Ma Inc EL USO DE INTERFERÓN-ß-1A EN LA ELABORACIÓN DE UN MEDICAMENTO Y UN ENVASADO DE TITULACIÓN QUE CONTIENE INTERFERÓN-ß-1A PARA REDUCIR LA SEVERIDAD DE LOS SÍNTOMAS TIPO GRIPE ASOCIADOS CON EL TRATAMIENTO DE UN PACIENTE QUE TIENE ESCLEROSIS MÚLTIPLE.
HUE043540T2 (hu) 2011-07-15 2019-08-28 Boehringer Ingelheim Int Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2838571A4 (en) * 2012-04-19 2016-02-10 Bard Inc C R INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it) * 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) * 2013-03-07 2014-11-05 安徽安科生物工程（集团）股份有限公司 一种重组人干扰素α2b制剂
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) * 2014-06-17 2014-11-06 株式会社スリー・ディー・マトリックス タンパク質の凝集抑制剤
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
JP7263320B2 (ja) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド 抗ベータアミロイド抗体を含有する医薬組成物
KR20210009982A (ko) * 2019-07-18 2021-01-27 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) * 2019-11-20 2023-04-07 迈克生物股份有限公司 蛋白c活性测定试剂盒
JP2023524248A (ja) * 2020-04-29 2023-06-09 アビオン インク． 二重突然変異を有するヒトインターフェロン－ベータ変異体及びヒトインターフェロン－ベータ変異体の安全性を向上させる方法
CN114177273A (zh) * 2021-11-29 2022-03-15 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
US20230210857A1 (en) * 2021-12-27 2023-07-06 Enalare Therapeutics Inc. Respiratory stimulant parenteral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57175125A (en) * 1981-04-20 1982-10-28 Wakunaga Yakuhin Kk Preparation of beta-interferon
EP0082481B2 (en) * 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon
TW249202B (pt) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
BR9507451A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
EE04266B1 (et) * 1996-12-24 2004-04-15 Biogen, Incorporated Interferooni stabiilne vedelkompositsioon

Also Published As

Publication number Publication date
ES2224290T3 (es) 2005-03-01
NZ512792A (en) 2002-11-26
KR101042660B1 (ko) 2011-06-20
NO327844B1 (no) 2009-10-05
DE69729880T2 (de) 2005-07-07
EA199900597A1 (ru) 2000-02-28
HK1025040A1 (en) 2000-11-03
CZ228299A3 (cs) 1999-12-15
PL193447B1 (pl) 2007-02-28
BR9714434A (pt) 2000-05-02
NZ336548A (en) 2001-09-28
KR20000069664A (ko) 2000-11-25
IL130524A (en) 2005-08-31
CZ300636B6 (cs) 2009-07-08
HK1092048A1 (en) 2007-02-02
TR199901968T2 (xx) 1999-12-21
CN1245434A (zh) 2000-02-23
HUP0000829A3 (en) 2002-01-28
EA002754B1 (ru) 2002-08-29
CN1733296A (zh) 2006-02-15
JP2007204501A (ja) 2007-08-16
ES2224290T5 (es) 2012-03-12
DE69729880T3 (de) 2012-05-10
DK0948358T4 (da) 2012-03-19
JP4878664B2 (ja) 2012-02-15
DE69729880D1 (de) 2004-08-19
NO993121L (no) 1999-08-24
AU5619198A (en) 1998-07-17
KR20070052363A (ko) 2007-05-21
SI0948358T1 (en) 2005-04-30
WO1998028007A1 (en) 1998-07-02
EP0948358B1 (en) 2004-07-14
BG65418B1 (bg) 2008-07-31
BG103594A (en) 2000-04-28
EE9900313A (et) 2000-04-17
EP0948358A1 (en) 1999-10-13
CN1222315C (zh) 2005-10-12
PL334365A1 (en) 2000-02-28
SK85899A3 (en) 2000-01-18
IL130524A0 (en) 2000-06-01
DK0948358T3 (da) 2004-11-08
HU224222B1 (hu) 2005-06-28
EE04266B1 (et) 2004-04-15
JP2011068694A (ja) 2011-04-07
JP2001519770A (ja) 2001-10-23
CA2275890C (en) 2011-11-01
MX337876B (es) 2016-03-22
SK284989B6 (sk) 2006-04-06
EE04223B1 (et) 2004-02-16
HUP0000829A2 (en) 2000-07-28
EP0948358B2 (en) 2011-11-23
NO993121D0 (no) 1999-06-23
ATE270899T1 (de) 2004-07-15
JP5851695B2 (ja) 2016-02-03
IS5087A (is) 1999-06-21
IS2070B (is) 2005-12-15
SI0948358T2 (sl) 2012-03-30
EE200300127A (et) 2003-06-16
AU738362B2 (en) 2001-09-13
CN1733296B (zh) 2010-05-26
JP2014098029A (ja) 2014-05-29
CA2275890A1 (en) 1998-07-02
BG65171B1 (bg) 2007-05-31
JP2012006979A (ja) 2012-01-12
BG109523A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
PT948358E (pt) Formulacoes de interferao liquidas e estaveis
CA2032499A1 (en) Polypeptide derivatives
AU586892B2 (en) Pharmaceutical and dietary composition
CA2085750A1 (en) Osteoinductive pharmaceutical formulations
DE3166150D1 (en) N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation
GR3035067T3 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins.
DE3483227D1 (de) Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung.
TW364850B (en) Nematocidal compositions
AR244544A1 (es) Composicion desodorante.
AU678421B2 (en) Highly concentrated TCF pharmaceutical preparations
AU3494093A (en) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
EP0063328A3 (en) Compositions containing secretin and method for preventing the adsorption of secretin
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
ZA837267B (en) Substituted n-carboxymethyl-(amino acid)-pyrrolidine-alkanoic acids useful as antihypertensive agents